Advertisement
Advertisement

Top 25 Most-Viewed Articles on The Body PRO

Long-Acting HIV Treatment: 5 Myths and Realities
Two-Drug HIV Treatment Regimens Effective in Latest Studies
'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?
The Need to Advocate for Fair HIV Drug Prices
Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity
Dose Reduction Potential of Nanoparticle ARV Formulations Confirmed in Humans
New Drugs, New Hope and Possible Timelines
Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies
Bictegravir -- An Emerging Integrase Inhibitor
The Capsid Inhibitor -- A New Class to Enter Clinical Trials
Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking
Running a PrEP Clinic in a Community Pharmacy Setting
Frame PrEP as Part of a 'Healthy Sex Life' for Better Adherence
Women's HIV Status, Viral Suppression Tied to Differences in Cognitive Performance Over Time
Less Than Half of People With HIV Who Are Eligible for Statins Receive Them
This Week in HIV Research: How Thailand Eliminated Mother-to-Child Transmission; and Maraviroc for Pre-Exposure Prophylaxis
New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps
3 Broadly Neutralizing Antibodies May Explain How Individual Controls HIV Without Treatment
New HIV Infections Drop 18% in 6 Years
Weekly Injections of Antibody PRO 140 Keep HIV Undetectable in 10 of 16 Patients
Bictegravir in the Body -- Preliminary Information About Drug Interactions
A New Nuke in the Works -- GS-9131
Mental Health Complications of HIV Insufficiently Studied
No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART
British Columbia Researchers Explore Life Expectancy Among HIV-Positive People




This article was provided by TheBodyPRO.com.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.